Lineage, Inc. Common Stock (LINE)vsSachem Capital Corp (SACH)
LINE
Lineage, Inc. Common Stock
$40.39
-1.32%
REAL ESTATE · Cap: $11.14B
SACH
Sachem Capital Corp
$0.93
+0.84%
REAL ESTATE · Cap: $45.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 36385% more annual revenue ($5.36B vs $14.69M). LINE leads profitability with a -2.7% profit margin vs -4.6%. SACH earns a higher WallStSmart Score of 45/100 (D+).
LINE
Avoid34
out of 100
Grade: F
SACH
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LINE.
Margin of Safety
+67.6%
Fair Value
$3.09
Current Price
$0.93
$2.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 1145.0%
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
Elevated debt levels
Smaller company, higher risk/reward
Elevated debt levels
ROE of -0.4% — below average capital efficiency
Revenue declined 46.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SACH
The strongest argument for SACH centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.15 suggests the stock is reasonably priced for its growth.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : SACH
The primary concerns for SACH are Market Cap, Debt/Equity, Return on Equity. Debt-to-equity of 1.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
LINE is growing revenue faster at 0.4% — sustainability is the question.
SACH generates stronger free cash flow (472,000), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SACH scores higher overall (45/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.
Visit Website →Sachem Capital Corp
REAL ESTATE · REIT - MORTGAGE · USA
Sachem Capital Corp. The company is headquartered in Branford, Connecticut.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?